Bepranemab is a monoclonal antibody commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Alzheimer’s Disease. According to Globaldata, it is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Bepranemab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Bepranemab is expected to reach an annual total of $5 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Bepranemab is under development for the treatment of progressive supranuclear palsy, prodromal/mild cognitive impairment due to Alzheimer's disease (AD) or mild Alzheimer's disease and tauopathies. The therapeutic candidate is a recombinant humanized IgG4P administered intravenously as a solution for infusion. It acts by targeting tau protein.
F. Hoffmann-La Roche Overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
The company reported revenues of (Swiss Francs) CHF63,281 million for the fiscal year ended December 2022 (FY2022), an increase of 0.8% over FY2021. The operating profit of the company was CHF17,476 million in FY2022, compared to an operating profit of CHF18,155 million in FY2021. The net profit of the company was CHF12,421 million in FY2022, compared to a net profit of CHF13,930 million in FY2021.
For a complete picture of Bepranemab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.